This is a chronological listing of grants held by this department, with the most recent listed first. New grants appear in this list weekly and contribute related to the department's Research Profile. The source of grants for this application comes directly from your institution.
SERCEB Southeast Regional Centers of Excellence for Biodefense and Emerging Infe
Fred Sparling; Ralph Baric; Aravinda Desilva; William Goldman; Mark Heise; Tom Kawula; Virginia Miller; Raymond Pickles; Lishan Su; Jenny Ting9/4/2003 - 2/28/2014
|Sponsoring Organization:||NIH National Institute of Allergy and Infectious Diseases (NIAID)|
|Awarding Organization Is:||University of North Carolina at Chapel Hill|
Aravinda M Desilva (Investigator)
Jenny P Ting (Investigator)
Lishan Su (Investigator)
Mark T Heise (Investigator)
P Fred Sparling (Lead Principal Investigator)
Ralph S Baric (Investigator)
Raymond J Pickles (Investigator)
Thomas H Kawula (Investigator)
Virginia L Miller (Investigator)
William Evan Goldman (Investigator)
Human metapneumovirus (hMPV) is a newly identified paramyxovirus that is associated with respitory infections in humans. Recent work in our laboratory demonstrates that this virus is one of the top two most frequent causes of lower respiratory tract disease in infants and children, along with respiratory syncytial virus (RSV). In the work of the parent grant, we have shown that immunication with an alphavisus vectored vaccine that presents the surface glycoproteins of hMPV or RSV in vaccinees in a conformationally authentic manner protects against hMPV or RVS disease. We have used a novel but established vaccine delivery system (VEE vector) to express hMPV or RSV surface glycoproteins. The VEE vector system offers advantages for resporatory tract immunization designed to elicit mucosal immunity. We have tested the immunogenicity and protective efficacy of the vaccine constructs in two small animal models, with outstanding results. The goal of t his administrative supplement request is to obtain funds to optimize the completion of preclinical testing and the preparation of human safety tested materials. The supplement would accelerate transition of this promising vaccine candidate toward clinical trials, and would enable us to create a new research assistance job. The work could be completed in the time frame appropriate for administrative suplements under the ARRA mechanism. The work is being performed at Vanderbilt University Medical Center and University of Wisconsin-Madison but funded through SERCEB.